Thu, Feb 20, 2020
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Net sales of UCITS and AIF close to historical peaks in August

Friday, October 27, 2017
Opalesque Industry Update - The European Fund and Asset Management Association (EFAMA) has published its latest Investment Funds Industry Fact Sheet, which provides net sales of UCITS and AIF for August 2017. 29 associations representing more than 99 percent of total UCITS and AIF assets provided us with net sales data.

The main developments in August 2017 can be summarized as follows:

· Net sales of UCITS and AIF totaled EUR 94 billion, slightly lower than EUR 96 billion in July.

· UCITS registered net sales of EUR 69 billion, down from EUR 83 billion in July.

o Long-term UCITS (UCITS excluding money market funds) recorded net sales of EUR 44 billion, down from EUR 61 billion in July.

o Net sales of equity funds totaled EUR 5 billion, down from EUR 19 billion in July.

o Net sales of bond funds totaled EUR 24 billion, down from EUR 29 billion in July.

o Net sales of multi-asset funds totaled EUR 14 billion, up from EUR 11 billion in July.

o UCITS money market funds registered net inflows of EUR 25 billion, higher than the EUR 22 billion registered in July.

· AIF recorded net sales of EUR 25 billion, up from the EUR 13 billion recorded in July.

· Total net assets of UCITS and AIFs totaled EUR 15,118 billion at end August, compared to EUR 15,059 billion at end July and EUR 14,147 billion at end 2016.

Bernard Delbecque, Senior director for Economics and Research at EFAMA commented: 'Net inflows into UCITS and AIFs remained close to historical peaks in August, despite a drop in net sales of equity funds against the background of rising geopolitical tensions caused by North Korea's missile tests.'

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. PE/VC: Venture debt: Is it a loan? Is it equity? Is it an pportunity?, PE, VC investments in India hit all-time high in 2019[more]

    Venture debt: Is it a loan? Is it equity? Is it an pportunity? From Forbes: Venture Capital is usually the default option for fast-growth startups looking for a cash injection, thanks to our willingness to take risks in return for equity, and with no need to pay anything back - at least

  2. Other Voices: Evolution of shrinking hedge fund fees - what do investors and managers need to know?[more]

    By Don Steinbrugge, Founder and CEO, Agecroft Partners (DonSteinbrugge@agecroftpartners.com): Hedge funds fees remain under extreme pressure across the industry. This strong trend is driven by declining return expectations from investors, inc

  3. COVID-19: Investors track ships, chase rumours to get edge on COVID-19 risks, Coronavirus risk puts the bull run on pause, China was wise to let markets stumble[more]

    Investors track ships, chase rumours to get edge on COVID-19 risks From Reuters: As investors crunch numbers to determine how the coronavirus will hit China's economy, hedge fund manager Nathaniel Polachek has tied much of his outlook to the fate of a ship anchored near Weihai, China.

  4. Bruce Berkowitz is back!, Coatue's new quant fund lost money in the fourth quarter[more]

    Bruce Berkowitz is back! From Institutional Investor: Famed value investor Bruce Berkowitz has hit hard times over the past decade, with big bets on losers like Eddie Lampert's Sears Holdings. In fact, over the past 10 years, his Fairholme Fund's annualized return is only 4.89 percent -

  5. Opalesque Exclusive: Optima A.M. bets on healthcare and biotech innovations with long/short strategy[more]

    B. G., Opalesque Geneva: Optima Asset Management has just launched the Optima Healthcare and Biotechnology strategy, which will be managed by five portfolio managers